TWI881480B - 克立咪唑(clemizole)化合物於預防及治療肝癌之用途 - Google Patents

克立咪唑(clemizole)化合物於預防及治療肝癌之用途 Download PDF

Info

Publication number
TWI881480B
TWI881480B TW112136665A TW112136665A TWI881480B TW I881480 B TWI881480 B TW I881480B TW 112136665 A TW112136665 A TW 112136665A TW 112136665 A TW112136665 A TW 112136665A TW I881480 B TWI881480 B TW I881480B
Authority
TW
Taiwan
Prior art keywords
liver
clemizole
compound
chloroquine
individual
Prior art date
Application number
TW112136665A
Other languages
English (en)
Chinese (zh)
Other versions
TW202402283A (zh
Inventor
傑佛瑞 S 葛蘭
愛德華 A 潘
Original Assignee
美商伊格集團國際股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商伊格集團國際股份有限公司 filed Critical 美商伊格集團國際股份有限公司
Publication of TW202402283A publication Critical patent/TW202402283A/zh
Application granted granted Critical
Publication of TWI881480B publication Critical patent/TWI881480B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW112136665A 2015-06-30 2016-06-30 克立咪唑(clemizole)化合物於預防及治療肝癌之用途 TWI881480B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
US62/187,061 2015-06-30

Publications (2)

Publication Number Publication Date
TW202402283A TW202402283A (zh) 2024-01-16
TWI881480B true TWI881480B (zh) 2025-04-21

Family

ID=57609247

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112136665A TWI881480B (zh) 2015-06-30 2016-06-30 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
TW111123545A TWI830262B (zh) 2015-06-30 2016-06-30 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
TW105120868A TWI771272B (zh) 2015-06-30 2016-06-30 克立咪唑（ｃｌｅｍｉｚｏｌｅ）化合物於預防及治療肝癌之用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW111123545A TWI830262B (zh) 2015-06-30 2016-06-30 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
TW105120868A TWI771272B (zh) 2015-06-30 2016-06-30 克立咪唑（ｃｌｅｍｉｚｏｌｅ）化合物於預防及治療肝癌之用途

Country Status (14)

Country Link
US (3) US10688083B2 (OSRAM)
EP (1) EP3317274A4 (OSRAM)
JP (3) JP7068827B2 (OSRAM)
KR (2) KR20180032578A (OSRAM)
CN (2) CN113274386A (OSRAM)
AU (4) AU2016288699B2 (OSRAM)
CA (2) CA2989634C (OSRAM)
HK (1) HK1249508A1 (OSRAM)
IL (4) IL300476B2 (OSRAM)
MX (3) MX394605B (OSRAM)
NZ (1) NZ776616A (OSRAM)
TW (3) TWI881480B (OSRAM)
WO (1) WO2017004454A1 (OSRAM)
ZA (2) ZA201708471B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394605B (es) * 2015-06-30 2025-03-24 Eiger Group Int Inc Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
EP3710831A4 (en) * 2017-11-15 2022-01-12 Beth Israel Deaconess Medical Center, Inc. MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS OF THE HEPATER
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
CN115515935B (zh) * 2020-04-30 2025-01-07 中美华世通生物医药科技(武汉)股份有限公司 冠状病毒感染的治疗或预防
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
CN102548394A (zh) * 2009-08-14 2012-07-04 雷维维科公司 用于糖尿病治疗的多转基因猪
CN101903026B (zh) * 2007-09-18 2013-05-08 斯坦福大学 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
TW200509958A (en) 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ZA200505996B (en) * 2003-02-14 2006-12-27 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
EP1656124A1 (en) * 2003-03-12 2006-05-17 Cerenis Methods and compositions for the treatment of cancer
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
US20090220583A1 (en) 2005-06-09 2009-09-03 Lena Pereswetoff-Morath Method and composition for treating inflammatory disorders
JP2009526070A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20100285001A1 (en) * 2007-10-02 2010-11-11 University Of Rochester Method and Compositions Related to Synergistic Responses to Oncogenic Mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US8975247B2 (en) * 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
ES2826950T3 (es) * 2009-05-27 2021-05-19 Ptc Therapeutics Inc Métodos para tratar cáncer y afecciones no neoplásicas
KR20120039742A (ko) * 2009-07-31 2012-04-25 가부시끼가이샤 스텔릭 사이세이 이카가꾸 겐뀨쇼 지방성 간염-간암 모델 동물
WO2011041311A2 (en) * 2009-09-29 2011-04-07 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
US20120202849A1 (en) * 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US8658787B2 (en) * 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
US9085578B2 (en) * 2012-02-20 2015-07-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20130273003A1 (en) * 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
JP6165848B2 (ja) * 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
TW201402556A (zh) * 2012-05-30 2014-01-16 Toyama Chemical Co Ltd 氘化含氮雜環羧醯胺衍生物或其鹽
US20140066469A1 (en) 2012-08-21 2014-03-06 Department Of Veterans Affairs Treatment of diseases associated with inflammation
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
BR112016011949A8 (pt) * 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
MX394605B (es) * 2015-06-30 2025-03-24 Eiger Group Int Inc Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
CN101903026B (zh) * 2007-09-18 2013-05-08 斯坦福大学 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途
CN102548394A (zh) * 2009-08-14 2012-07-04 雷维维科公司 用于糖尿病治疗的多转基因猪

Also Published As

Publication number Publication date
MX2017016681A (es) 2018-07-06
AU2021201234A1 (en) 2021-03-11
IL279020B2 (en) 2023-07-01
CN113274386A (zh) 2021-08-20
BR112017028601A2 (pt) 2018-08-28
US20240398761A1 (en) 2024-12-05
IL279020B1 (en) 2023-03-01
IL300476B2 (en) 2024-07-01
AU2016288699A1 (en) 2018-01-18
IL256233A (en) 2018-02-28
NZ738291A (en) 2021-06-25
CA2989634C (en) 2022-12-06
CA3178499A1 (en) 2017-01-05
AU2023201397B2 (en) 2024-10-03
WO2017004454A1 (en) 2017-01-05
TW201717941A (zh) 2017-06-01
IL279020A (OSRAM) 2020-12-31
JP2018519340A (ja) 2018-07-19
JP2024083475A (ja) 2024-06-21
AU2024266943A1 (en) 2024-12-19
HK1249508A1 (zh) 2018-11-02
US20210052553A1 (en) 2021-02-25
US12090141B2 (en) 2024-09-17
US10688083B2 (en) 2020-06-23
MX394605B (es) 2025-03-24
IL310969A (en) 2024-04-01
AU2023201397A1 (en) 2023-04-06
TW202317103A (zh) 2023-05-01
TWI771272B (zh) 2022-07-21
JP7068827B2 (ja) 2022-05-17
ZA202004136B (en) 2025-08-27
EP3317274A4 (en) 2019-05-08
MX2023003792A (es) 2023-04-26
TW202402283A (zh) 2024-01-16
AU2016288699B2 (en) 2020-11-26
WO2017004454A8 (en) 2018-01-25
KR20180032578A (ko) 2018-03-30
US20180200228A1 (en) 2018-07-19
ZA201708471B (en) 2022-05-25
MX2022008100A (es) 2022-07-11
CN107922404B (zh) 2021-06-29
CA2989634A1 (en) 2017-01-05
CN107922404A (zh) 2018-04-17
NZ776616A (en) 2024-11-29
IL300476B1 (en) 2024-03-01
EP3317274A1 (en) 2018-05-09
TWI830262B (zh) 2024-01-21
JP2022105149A (ja) 2022-07-12
JP7470151B2 (ja) 2024-04-17
KR20230129590A (ko) 2023-09-08
IL300476A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
TWI881480B (zh) 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
KR20170130615A (ko) (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
KR101888779B1 (ko) Ａｍｐｋ 활성을 증진시킬 수 있는 약물을 제조하기 위한 이소퀴놀린 알칼로이드 유도체의 용도
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
NZ738291B2 (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
KR101427291B1 (ko) 알콕시페닐프로펜온 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 다약제 내성 억제용 약학적 조성물
KR20240111305A (ko) 페롭토시스 유도 활성을 갖는 화합물
BR112017028601B1 (pt) Uso de clemizol
WO2024178425A1 (en) Hydroxyalkyl and methoxyalkyl tryptamines